Loading
A phase 1/2 trial of Sacituzumab tirumotecan, Fluorouracil, FLOT in colorectal cancer and pancreatic ductal adenocarcinoma, run by Merck Sharp & Dohme LLC, now recruiting.
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) is a phase 1/2 interventional study registered as NCT06428409 by Merck Sharp & Dohme LLC, with 220 participants planned, started 2024-06-20 and due to reach its primary completion in 2029-10-16. Interventions recorded: Sacituzumab tirumotecan, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin, Rescue medication, Supportive care measures. Conditions listed: Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer. No results are recorded here; the registry entry is the source.
Shares Sacituzumab tirumotecan, Fluorouracil (5-FU), Merck & Co. (MSD), Pembrolizumab.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Fluorouracil (5-FU), Colorectal cancer.
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Cisplatin, Pembrolizumab.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Fluorouracil (5-FU), Colorectal cancer.
Shares Fluorouracil (5-FU), Merck & Co. (MSD), Cisplatin, Pembrolizumab.
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Cisplatin, Pembrolizumab.
Shares Sacituzumab tirumotecan, Fluorouracil (5-FU), Merck & Co. (MSD), Pembrolizumab.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Cisplatin, Pembrolizumab, Colorectal cancer.